Introduction
Retinoic acid (RA) is an active derivative of vitamin A that influences a range of essential biological processes such as development and homeostasis (1) (2) (3) (4) . RA exerts its action through nuclear RA receptors (RARs), which are typical ligand-dependent regulators of transcription with a central DNA binding domain (DBD) linked to a Ligand-Binding Domain (LBD) (for review see (5, 6) ). In response to RA signaling, RARs heterodimerize with retinoid X receptors (RXRs) and occupy characteristic RA response elements (RAREs) located in the promoter of target genes involved in cell proliferation and differentiation. RXR/RAR 2 heterodimers occupancy at cognate response elements is commonly a determinant of transcriptional responsiveness. Within a given cell type, binding of RXR/RAR heterodimers to RAREs can either up-or down-regulate transcription in a gene-specific manner. RAREs are composed of two direct repeats of a core hexameric motif (A/G)G(G/T)TCA. The classical RARE is a 5-bp-spaced direct repeat (referred to as a DR5), but RXR/RAR heterodimers can also bind to direct repeats separated by 2 bp (DR2) or 1 bp (DR1) (6, 7) .
The development of high throughput technologies such as DNA microarrays revealed that, within a given cell type or tissue, the RA response is composed of a huge and complex network of responsive genes (8) (9) (10) . However such techniques could not discriminate between direct primary and secondary target genes (which are modulated by the product of a primary target gene rather than by RXR/RAR heterodimers) and only a few of the RA-target genes contained identified RAREs. More recently, chromatin immunoprecipitation (ChIP) coupled with array hybridization allowed the identification of new RAR binding loci (11, 12) . However whether such loci bind RARs directly or indirectly through other bound factors could not be easily discriminated. Moreover, the identified loci do not correspond to the full repertoire as the arrays do not represent all possible regions in a genome. The nascent genome-wide ChIP-seq (ChIP coupled with deep sequencing) technology should expand the repertoire of potential high affinity response elements (13, 14) . Nevertheless, though powerful, such ChIP-based approaches are highly cell context specific. Now, with the availability of an increasing number of genome sequences, in silico analysis of RAREs can be also performed. The advantage of computational techniques is that it overcomes the chromatin structure and thus the cellular context and provides a direct glance on the whole repertoire of possible RAREs.
Here we conducted a genome-wide in silico study of RA response elements. Though RXR-RAR heterodimers can bind to DR5, DR2 or DR1 response elements, the significance and the specificity of the DR2 and DR1 is still unclear. Therefore we focused on DR5 RAREs. Computational techniques were developed for the genome-wide identification of DR5 RAREs and for the characterization of their genomic and phylogenetic context. In this way, we amassed a collection of DR5 RAREs that are conserved across vertebrate species and that were validated for their occupancy and functionally analyzed for the RA-responsiveness of the associated genes. Such a strategy allowed us to characterize a new set of high confidence conserved DR5 RAREs associated to a series of new potential RA-target genes, thus providing a wider knowledge base for the analysis of the RA response in different species.
3 the quality of their annotation and for their repartition through the vertebrate phylogenetic tree: zebrafish (danRer5), fugu (fr2), xenopus (xenTro2), lizard (anoCar1), chicken (galGal3), platypus (ornAna1), opossum (monDom4), dog (canFam2), horse (equCab1), cow (bosTau4), rat (rn4), rhesus (rheMac2), and chimpanzee (panTro2). We considered a motif as conserved in a given species if the region encompassing the motif in human or mouse is aligned with a genomic region of the species also containing a RGKTSA DR5 motif Cell culture, RNA extraction and qRT-PCR F9 and P19 mouse embryocarcinoma cells, human MCF7 cells and zebrafish PAC2 cells were cultured according to standard conditions as previously described (16) (17) (18) (19) . RNAs were extracted and subjected to qRT-PCR as previously described (20). Transcripts were normalized according to the ribosomal protein gene RPLP0. All mouse primers are listed in supplemental Table S1 . The others are available upon request.
RNA-sequencing
After isolation of total RNA, a library of template molecules suitable for high throughput DNA sequencing was created according to the instructions of Illumina. Briefly, the polyAcontaining mRNAs were isolated from total RNA (4mg) by two-runs of purification on SeraMag Oligo-dT Beads and fragmented using divalent cations and heat-catalyzed hydrolysis. Fragmented mRNAs were used as a template to synthesize single-stranded cDNA with Superscript II reverse transcriptase and random primers. After second strand synthesis, the cDNAs went through end-repair and ligation reactions using paired-end adapter oligos from Illumina and were electrophoresed on an agarose gel. A slice containing fragments in the 300-bp range was excised and after elution and purification, the library was amplified with 15 cycles of PCR with Illumina sequencing primers and purified using Agencourt AMPure XP beads from Beckman.
The library was then used to build clusters on the Illumina flow cell according to protocol. Image analysis and base calling was performed using the Illumina pipeline. Reads were then mapped onto the mm9/NCBI37 assembly of the mouse genome using Tophat (21). Quantification of gene expression was done using Cufflinks (22) and annotations from Ensembl release 57. For each transcript the number of FPKM (fragments per kilobase of transcript per million fragments mapped) were converted into raw read counts, which were added for each gene locus by using an R script that we implemented. Then, data normalization and identification of significantly differentially expressed genes were performed with the method proposed by Anders et al. (23) and implemented into the DESeq Bioconductor package. The final p-values were adjusted for multiple testing according to the method proposed by Benjamini and Hochberg (24) and a cutoff p value of 0.05 was applied for finding significant responsive genes.
RESULTS
Bioinformatic genome-wide research of DR5 RAREs corresponding to the RGKTSA motif.
Only a few RAREs have been identified to date and associated to RA-target genes. Most of them are represented by two direct repeats of the hexameric motif (A/G)G(G/T)TCA, separated by 5 nucleotides (DR5) (25,26). Such DR5 have been found in the promoters of human and mouse genes involved in RA metabolism (Cyp26A1) (27), in RA signaling (RARα2, RARβ2, RARγ2) (28-30) or in development (Hoxa1, Hoxa4, Hoxb1) (31-33). Alignment of these RAREs (Fig. 1) clearly delineates a recurrent motif RGKTSA (coding is according to the IUPAC convention: R= AG; K=GT; S=CG), which differs from the classical consensus motif RGKTCA at position 5, with a G instead of a C (in RARγ2 and Hoxa4). Therefore with the aim of identifying novel RA-driven primary target genes, we screened the masked human and mouse genomes for DR5 corresponding to two direct repeats of the RGKTSA motif at the genome-wide scale (see materials and methods). Such in silico screens have the potential of identifying target genes independently of their tissue of expression. We identified 15925 DR5 corresponding to two direct repeats of the RGKTSA motif in the mouse genome and 14571 in the human genome (supplemental Tables S2  and S3 ). 4 they are conserved between species (phylogenetic footprinting). Indeed, highly in vivo relevant DR5 RAREs are expected to be conserved and thus to be under an ancient strong selective constraint. Therefore, in order to delineate functional RAREs, we analyzed the conservation of the human and mouse RAREs across 13 additional vertebrate organisms (see materials and methods) by using the BlastZ alignment of the UCSC genome browser. Due to the shortness and the divergence of the RGKTSA sequence, the criterion of conservation was deduced from the presence/absence of the complete D R 5 m o t i f RGKTSANNNNNRGKTSA in all considered genomes. We considered that a motif was conserved in a given species if the region encompassing the motif in human or mouse is aligned with a genomic region of the species also containing a RGKTSA DR5 motif (see material and methods).
In a phylogeny of vertebrates, we visualized the number of human or mouse RAREs that are conserved in each studied species (Fig. 2) . We also calculated for each relevant clade of vertebrates, the number of RAREs that are conserved in all the members of these clades. Though these data can be influenced by the coverage of the studied genome (34), this analysis raised three interesting conclusions (i) Overall, human RAREs are less conserved in rodents than in other mammals. As an example, about 900 human RAREs are conserved in the mouse genome while more than 1500 are conserved in the cow genome. This is in accordance with the known increased evolutionary rates in rodents (35) 
Genome-wide analysis of the location of the identified DR5 RAREs
The identified mouse and human RAREs were also annotated by analyzing genome-wide their locations, using the GeCo system (see Materials et methods), which allows users to retrieve the genes in the neighborhood of factor binding sites with respect to annotated Refseq genes (Anno et al., manuscript in preparation). Then, in both the human and mouse genomes, the RAREs were localized relative to the nearest matched gene boundary: upstream and downstream distance from the Transcription Start Site (TSS) and from the end of genes. As shown in Figures 3A and 3B , the regions flanking TSSs and the ends of genes depict the highest concentration of RAREs compared to the further regions (±500 kb). This suggests that the RAREs located in the vicinity of TSSs and gene ends would be more relevant than the others, as described for most nuclear receptors and transcription factors (14, (42) (43) (44) (45) (46) . Therefore, we selected the RAREs located between -10kb and +10kb, i.e. the RAREs ±10kb from the TSSs and ±10kb from gene ends. According to this criterion, 3862 RAREs were selected in the mouse genome and 3429 in the human one (supplemental Tables S2 and S3 ).
Selection of a list of RAREs located ±10kb from gene limits and conserved in 6 organisms or more
Considering the low number (6) of highly conserved RAREs and the overall repartition of the 15 organisms among the vertebrate tree, we arbitrary selected a criterion of conservation in 6 organisms. Only 7% of the human RAREs (1049 sites) ( Fig. 4A ) and 5% of the mouse RAREs (766 sites) (Fig. 4B ) were found to be conserved in 6 organisms and more.
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Then these human and mouse RAREs conserved across 6 and more organisms were further analyzed for their localization relative to the matched gene annotations Among these RAREs, 238 human RAREs and 181 mouse RAREs were found to be located at proximity of genes in the ±10kb regions that we defined above ( Fig. 4C and 4D and supplemental tables 2 and 3). By using these two criteria of restriction we obtained a list of 138 RAREs that are common to both mouse and human organisms and that are reliable in terms of genome annotation, name of the corresponding genes, localization and conservation in more than 6 organisms (Fig. 5) .
The orientation and localization of each conserved RARE listed in Figure 5 were compared. Most interestingly, 100% of these RAREs showed the same orientation in the human and mouse genomes and approximately 70% showed less than 500 bp difference in their distances to the nearest associated genes ( Fig.  4E ), suggesting that these RAREs are good candidates for being functional. Moreover, 43 RAREs located in exons, 49 in introns and 30 in promoters correlated well between the two genomes ( Fig. 4F) . The other RAREs, though associated with a same gene in both genomes, depicted different localizations most probably due to differences in genes annotations between the two genomes. Note that three RAREs associated with Hox genes differed between both genomes, most probably due to the complex organization and evolution of the Hox clusters.
RAR binding to the selected DR5 RAREs and analysis of the associated genes
Then the key question to address was whether the DR5 RAREs that we selected in silico reflect biological significance in vivo, in other words, whether they are able to bind RAR/RXR heterodimers. To address this, we first crossed the list of 15925 DR5 RAREs found in the mouse genome with the RAR and RXR binding sites mapped in ChIP-seq experiments (Benoit et al, manuscript in preparation) performed with a mouse embryocarcinoma cell line (F9 cell lines), which is well known to respond to RA (1) . In these cells, 4% of these RAREs were occupied by RAR/RXR heterodimers in the absence of RA (Table 1) . This percentage increased up to 9% after 48 hours of RA treatment. In fact, taking into account that some sites become occupied while others dissociate from RAR/RXR heterodimers in response to RA, 11 % of the RAREs were found to be able to bind RAR/RXR heterodimers ( Table 1) . As a control, a random list of 15925 17bp sequences extracted from the mouse masked genome (Supplemental Table S4 ), was crossed with the same binding sites (Table 1) .
Most interestingly, the percentage of occupied RAREs increased up to 42% when the same crossing was applicated to the list of 181 conserved mouse RAREs and to our final in silico list of 138 RAREs (Table 1) , thus validating our strategy.
Among these RAREs (Table 2) , 39 were occupied in the absence of RA, among which 17 depicted an important increase in their occupancy in response to RA. In addition 19 RAREs, though unoccupied in the absence of RA, became occupied after RA addition, raising to 58 the number of RAREs that can be occupied in F9 cells. Note that the increase in occupancy started rapidly (within 2h) or later (24-48h); depending on the RARE.
Some of these RAREs have been already reported to be direct RAR targets in EMSA, ChIP or ChIP-chip experiments. It is the case for the canonical RAREs associated to the wellknown RA-target genes involved in transcription regulation such as RARβ2, Hoxa1, Hoxb1 and Wt1 (19,32,47-50) or in RA metabolism (Cyp26A1, Rbp1). Most interestingly, this analysis revealed that two RAREs are associated to the RARb2, Wt1 and Cyp26A1 genes. However, only one of the RAREs associated to the Wt1 and Cyp26A1 genes was occupied in F9 cells, while both RAREs associated to the RARβ2 gene were occupied. Of note is that for RARβ2, the RARE located in the promoter was more efficiently occupied than the other one, located in an exon, increasing the complexity of the transcriptional regulation of this gene in F9 cells.
Other occupied RAREs were associated to genes that are already known as RA responsive genes but for which no RAREs had been identified yet. Among these genes are the "Stimulated by RA" (Stra) genes such as Bhlhb40 (Stra13) (51), Tcfap2C (Stra2) (52) and Meis2 (Stra10) (53) and zinc finger proteins (Zfp598 and Zfp503) (8, 10) . Note that three RAREs are associated to the Meis2 gene but that only two were occupied by RAR/RXR heterodimers in F9 cells. The analysis also revealed occupied RAREs associated to gene regulatory regions, which were recently found to be occupied by RARs in ChIP-chip and ChIP-6 qPCR experiments performed with other cell lines, but without any indication whether this occupancy was direct or indirect through other bound factors (11) . This is exemplified by the RAREs associated to the Atxn2, Top2b, Wnt1 and Wnt5 genes.
Most interestingly, a new repertoire of occupied RAREs was found to be associated to new potential RA-target genes encoding transcription regulators (RXRβ, Jmjd3, Foxa2), several Homeobox genes belonging to clusters (Hoxa3, Hoxb3, Hoxd3), galectins (Lgals2), membrane associated proteins (Sema3e, Abhd2, Crygn), RNA binding proteins (Cugbp1, Qk, Srp68, Pcbp4), ATPases (Clpb) and proteins involved in cell death (Sspn), neuronal functions (Agap1), developmental processes (Otp), cell signaling (Raph1, Arpp21, Zdhhc3, Cacna1g, Camk2b, Ephb3, Pld2) and cytoskeleton organization (Ivns1abp). RAREs were also found associated to the tumor suppressor HIC1 gene, the kallikrein-related peptidase 13 (KLK13) gene, the Myf6 gene, which belongs to the family of muscle regulatory factors (MRFs) and the Prss27 gene which encodes a membraneanchored protease. Note that in the two latter cases, the occupation of the sites decreased after RA addition.
The other RAREs of the bioinformatics list were not occupied by RARs in F9 cells either in the absence or presence of RA. However, as RAR binding relies on the cellular and/or physiological context, one cannot exclude that these RAREs would be occupied in other cell lines or tissues or in other species.
RA-regulation of the genes associated to the selected RAREs
Next we assessed whether the genes associated to the selected RAREs are RAregulated. Our in silico screen identified 138 DR5 RAREs, but taking into account that several RAREs were found associated to a same gene, there are 129 potential RA-regulated genes. First, the set of RA-regulated genes was analyzed by high throughput qPCR sequencing (RNA-seq) using F9 cells for which we already had a list of 58 occupied DR5 RAREs. A list of 167 genes that were either induced or repressed after a 4 hours treatment with RA, was generated after data normalization and identification of the significant differentially expressed genes (supplemental Table S5 ). This list was finally reduced to 164 distinct genes after removal of the duplicated genes.
Then this list of 164 RA-regulated genes was crossed with the list of 129 RAREassociated genes raised in silico, resulting in the selection of 9 RA-responsive genes common to the two lists (Fig. 6 ). This list includes indeed the canonical RAR target genes (Cyp26A1, RARβ2, Rbp1, Hoxa1 and Hoxb1). It also includes two new Hox genes (Hoxa3, Hoxb3) as well as two new Stra genes, Tcfap2C and BHBLH4. In F9 cells, for all these 9 RAresponsive genes, the associated DR5 RAREs were occupied by RAR/RXR heterodimers and this occupancy was increased in response to RA (see Table 2 ).
Note that several other genes that are not in our bioinformatics list are activated in RAtreated F9 cells. However, some rely on other DR elements (cdx1) and/or reflect the complexity of Hox clustering (Hoxa5, Hoxb5, Hoxa4, and Hoxb2) (54) (55) (56) (57) . Others are known RA responsive genes (1,58-60) with DR5 RAREs (see Supplemental table S2), but are not conserved in several species (Cyp26B1, Stra6, Stra8, Foxa1, Gbx2/Stra7) or are located out of the ±10kb limits (Gata6).
The RA responsiveness of the genes we selected in silico was also analyzed in qRT-PCR experiments performed with F9 cells after RA treatment for different times up to 8 hours. According to the confidence of the quality of their annotation and sequencing, 49 genes among the 129 ones (Supplemental table 1) were analyzed. This approach confirmed the RAinducibility of the 9 genes selected above ( Fig.  7A-D) . Interestingly, it also revealed that the inducibility of these genes increases with time ( Fig. 7A-D) . Moreover, some additional RARbound genes, such as Meis2, KLK13 and HIC1, can be also activated in response to RA but with a low efficiency and at later times (8 hours) (Fig.  7D-E) , raising to 12 the list of RA responsive genes controlled by conserved DR5 RAREs and located ±10kb from TSSs, in F9 cells (Fig. 6) .
Given that the RA response of target genes is well known to be cell type specific, the same qRT-PCR experiments were performed with another RA responsive mouse embryocarcinoma cell line, the P19 cell line. As shown in Figure 7 (F-J), the same genes were activated in response to RA, though with different intensities and kinetics. As an example, the Hoxa1 and Meis2 genes were more efficiently activated in P19 cells than in F9 cells. Note that the Myf6 gene, which was not activated in F9 cells, responded to RA in P19 cells (Fig. 7   7I ), raising the number of RA responsive genes to 13.
Finally, as the RAREs controlling these 13 genes are highly conserved between species (Fig. 5) , we analyzed whether they also responded to RA in other cell lines from other species such as a human breast cancer cell line (MCF7 cells) (Fig. 8A ) and a zebrafish cell line (PAC2) (Fig. 8B) . The Bhlhe40 gene was significantly activated in MCF7 cells but not in zebrafish PAC2 cells. In contrast, Meis2 was strongly activated in PAC2 cells and not in MCF7 cells. These results are summarized in Figure 9 and point out that the RA response of the new RARE-associated genes we identified may vary from one cell type to the other and from one species to the other.
DISCUSSION
Here we describe a genome-wide in silico analysis of consensus DR5 RAREs with recurrent RGKTSA motifs. The advantage of such a computational approach is that it overcomes the chromatin and cellular context and thus provides a direct glance on the whole repertoire of possible RAREs. Moreover the choice of recurrent RGKTSA motifs was expected to expand this repertoire of RAREs.
This computational study revealed around 15000 DR5 RAREs in the human and mouse genomes. Among these RAREs, 24% are concentrated in regions located ±10kb from the TSSs and the gene ends, and 5-7 % are conserved in 6 organisms or more. It also revealed that the degree of conservation of the overall RAREs is not linear with time in the various vertebrates and that the RA gene regulatory network is specifically elaborated in specific groups. Surprisingly, this occurred specifically in placental mammals (Eutherians) versus all Mammals. Indeed, three fold more RAREs are conserved in the former than in the latter. As no major events of genomic reorganization are known to have occurred at the base of placental mammals, this elaboration might be specific to RA signaling.
Finally it provided a list of 138 RAREs located ±10kb from TSSs and gene ends and conserved in 6 organisms or more. This list includes the majority of known RAREs, validating the restrictive criteria of our analysis. It also includes RAREs associated to "stimulated by RA" (Stra) genes for which no RAREs had been identified yet. The interesting point is that it provided a newly expanded set of high confidence conserved DR5 RAREs associated to a series of new genes involved in transcription, cell signaling, development, neuronal functions and tumor suppression. The other interesting point is that, in some cases, two to three RAREs were found to be associated to a same gene (e.g. Cyp26A1, RARβ2 and Meis2), increasing the complexity of the transcriptional regulation of these genes.
However, in silico identification of RAREs does not assure their functionality Therefore we combined the present computational analysis to experimental biology in order to determine whether the selected RAREs can bind RARs (ChIP-seq) and respond to RA (RNA-seq and qRT-PCR). Such an integrated strategy performed with mouse embryocarcinoma cells (F9 cell line), revealed that 11% of the 15925 mouse RAREs present in the starting list were occupied bu RAR/RXR heterodimers. Interestingly, this percentage increased to 40% in the final list of conserved RAREs located ±10kb from TSSs, validating our selection strategy.
Of note is that, in F9 cells, among the 58 occupied RAREs of our final list, only 12 of the corresponding genes were rapidly activated in response to RA. These genes include indeed the canonical RA target genes (Cyp26A1, RARβ2, Rbp1, Hoxa1, Hoxb1) as well as new Hox genes (Hoxa3 and Hoxb3), Stra genes (Tcfap2c, Bhlhe40, Meis2), HIC1 and KLK13. These 12 genes were also activated in another mouse embryocarcinoma cell line (P19). However some of them (exemplified by the Bhlhe40 and Meis2 genes) did not respond to RA in human MCF7 cells or in zebrafish PAC2 cells. In contrast, another gene, Myf6, which was occupied but not RA responsive in F9 cells, was significantly induced in P19 cells. This corroborates that the RA regulation of target genes differs from one cell type to the other (Fig. 9) , most probably in line with their chromatin context and final feature (differentiation or proliferation). In fact, the majority of the genes associated to occupied RAREs were not RA-regulated in F9 cells. This lack of RA response may be due to the fact that the genes are already expressed (and thus cannot be further stimulated). However one cannot exclude that RA-regulation requires longer times as exemplified for Zfp503 (10), specific RAREmediated conformational changes of the bound RAR (61) and/or crosstalks with other signaling pathways (12,62), emphasizing the complexity 8 of the RAR-mediated regulation of gene expression Remarkably, the majority of the RAREs present in our in silico list were not occupied in vivo, in F9 cells. This is not surprising as RAR binding relies on the cellular and physiological context and/or may require other cell specific transcription factors (12). Thus, one can predict that the other RAREs present in the in silico list would be occupied in other appropriate cell types or tissues with the corresponding genes being RA regulated under specific conditions.
The final interesting point of this study is the identification of 6 RAREs that are conserved in all the 15 species studied. However, except the RARE associated to the Gria2 gene, all these RAREs are located out of the ±10kb limits we defined. Moreover, none of the corresponding genes were RA-regulated in F9 cells, as assessed in RNA-seq experiments, except Meis1, which was activated 24 hours following RA addition to F9 cells (10) . Nevertheless, these genes are mostly developmental genes (36-41) that are expressed in specific cell types and tissues and at specific developmental stages. Therefore they might be new markers of the RA response, valid at specific times, in specific tissues from any jawed vertebrate species, opening new avenues for the study of RA signaling during development.
In conclusion, the novelty of the present study resides in an integrated strategy combining genome-wide biocomputing analysis and biological experiments, for discovering and characterizing new RAR-target genes and response elements. In addition to providing a wider valuable knowledge base for the analysis of robust RA-responsive genes, such a strategy also brought significant biological informations. Indeed, it revealed (i) low conservation of RAREs between human and mouse (6%) and significant differences in the RA-regulation of the highly conserved RAR-target genes between species. Thus it suggests that the RA response will differ from one species to the other as well as from one tissue to the other, and under different situations. Finally, one can predict that the small set of conserved RAR-direct target genes would act as key effectors of evolutionary steps." Endocrinol 6, 2197-2209 17.
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